|
|
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Found 20 studies with search of: | "Delavirdine mesylate" [TREATMENT] AND HIV [CONDITION] |
|
Hide studies that are not seeking new volunteers.
|
|
| 1 | Completed | A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Indinavir sulfate; Drug: Delavirdine mesylate; Drug: Lamivudine; Drug: Zidovudine | |||||
| 2 | Completed | A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Delavirdine mesylate | |||||
| 3 | Completed | A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Indinavir sulfate; Drug: Delavirdine mesylate; Drug: Zidovudine | |||||
| 4 | Completed | Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Indinavir sulfate; Drug: Delavirdine mesylate; Drug: Lamivudine; Drug: Stavudine; Drug: Zidovudine | |||||
| 5 | Completed | A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Delavirdine mesylate; Drug: Zidovudine; Drug: Didanosine | |||||
| 6 | Completed | A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3 | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Delavirdine mesylate; Drug: Didanosine | |||||
| 7 | Completed | A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3 | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Delavirdine mesylate; Drug: Lamivudine; Drug: Zidovudine | |||||
| 8 | Terminated | A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Lamivudine/Zidovudine; Drug: Nelfinavir mesylate; Drug: Saquinavir; Drug: Delavirdine mesylate | |||||
| 9 | Terminated | The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Emivirine; Drug: Hydroxyurea; Drug: Delavirdine mesylate; Drug: Stavudine; Drug: Didanosine | |||||
| 10 | Completed | A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Indinavir sulfate; Drug: Delavirdine mesylate; Drug: Lamivudine; Drug: Zidovudine | |||||
| 11 | Completed | Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Nelfinavir mesylate; Drug: Delavirdine mesylate; Drug: Stavudine; Drug: Didanosine | |||||
| 12 | Completed | Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S) | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Delavirdine mesylate; Drug: Zidovudine; Drug: Didanosine | |||||
| 13 | Completed | A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Ritonavir; Drug: Nelfinavir mesylate; Drug: Levocarnitine; Drug: Adefovir dipivoxil; Drug: Saquinavir; Drug: Delavirdine mesylate | |||||
| 14 | Completed | The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Delavirdine mesylate; Drug: Zidovudine | |||||
| 15 | Terminated | Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Indinavir sulfate; Drug: Ritonavir; Drug: Delavirdine mesylate | |||||
| 16 | Completed | A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Ritonavir; Drug: Nelfinavir mesylate; Drug: Saquinavir; Drug: Delavirdine mesylate | |||||
| 17 | Completed | A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Ritonavir; Drug: Nelfinavir mesylate; Drug: Saquinavir; Drug: Delavirdine mesylate; Drug: Lamivudine; Drug: Stavudine; Drug: Zidovudine | |||||
| 18 | Completed | Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 | ||||
| Condition: | HIV Infections | |||||
| Interventions: | Drug: Ritonavir; Drug: Saquinavir; Drug: Delavirdine mesylate; Drug: Lamivudine; Drug: Stavudine; Drug: Zidovudine; Drug: Didanosine | |||||
| 19 | Recruiting | Clinical Trial of CNS-Targeted HAART (CIT2) | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: FDA Approved Antiretroviral Therapy (see list below) | |||||
| 20 | Not yet recruiting | Safety and Effectiveness of Addition of Maraviroc to ART Regimens in HIV-Infected Adults With Suboptimal CD4 T-Cell Count Recovery Despite Sustained Virologic Suppression | ||||
| Condition: | HIV Infections | |||||
| Intervention: | Drug: Maraviroc | |||||